{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:53:44Z","timestamp":1791996824915,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Almirall"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AnaptysBio"},{"DOI":"10.13039\/100016792","name":"Asana Biosciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016792","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dermavant"},{"name":"DS Biopharma"},{"name":"Eli Lilly"},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ichnos Sciences"},{"name":"Innovaderm"},{"name":"Janssen"},{"name":"Kiniska"},{"DOI":"10.13039\/100016348","name":"Kyowa Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leo Pharma"},{"name":"Novan"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ralexar"},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sienna Biopharma"},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Union Therapeutics"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jaad.2020.08.051","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T11:45:17Z","timestamp":1597751117000},"page":"139-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":273,"title":["Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"84","author":[{"given":"Anne-Sofie","family":"Halling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.08.051_bib1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2020.08.051_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2020.08.051_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17512433.2018.1449642","article-title":"Dupilumab for treatment of atopic dermatitis","volume":"11","author":"Seegraber","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jaad.2020.08.051_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.08.051_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2020.08.051_bib6","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.08.051_bib7","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.051_bib9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.18163","article-title":"Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study","volume":"181","author":"Uchida","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.08.051_bib10","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.15609","article-title":"Treatment of atopic\u00a0dermatitis with dupilumab: experience from a tertiary\u00a0referral centre","volume":"33","author":"Olesen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.08.051_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.051_bib12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jaad.2020.08.051_bib13","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/bjd.17629","article-title":"Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice","volume":"180","author":"Tauber","year":"2019","journal-title":"Br J Dermatol"},{"issue":"9 suppl","key":"10.1016\/j.jaad.2020.08.051_bib14","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/j.jid.2019.07.131","article-title":"127 TREATGermany registry: \u201creal-world effectiveness\u201d of dupilumab in atopic dermatitis","volume":"139","author":"Weidinger","year":"2019","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jaad.2020.08.051_bib15","first-page":"1","article-title":"Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis","author":"Fargnoli","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2020.08.051_bib16","unstructured":"Ferrucci SM, Tavecchio S, Angileri L et\u00a0al. Impact of dupilumab on quality of life in patients with moderate-to-severe atopic dermatitis. Abstract from the 28th EADV Congress. Madrid2019."},{"key":"10.1016\/j.jaad.2020.08.051_bib17","article-title":"Real-life practice: rapid\u00a0improvement in itch symptomatology in patients with atopic dermatitis treated with dupilumab","author":"Pistone","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.051_bib18","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.18041","article-title":"Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series","volume":"181","author":"Armario-Hita","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.051_bib19","doi-asserted-by":"crossref","first-page":"e12931","DOI":"10.1111\/dth.12931","article-title":"Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series","volume":"32","author":"Ruiz-Villaverde","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2020.08.051_bib20","unstructured":"Fernandez CPH, Rodriguez SH, Morales PD et\u00a0al. Dupilumab in real world practice for moderate to severe adult atopic dermatitis: our experience in a third-level referral Spanish academic hospital. Abstract from the 28th EADV Congress. Madrid2019."},{"key":"10.1016\/j.jaad.2020.08.051_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/00015555-3121","article-title":"Eye complications during dupilumab treatment for severe atopic dermatitis","volume":"99","author":"Ivert","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"suppl 231","key":"10.1016\/j.jaad.2020.08.051_bib22","first-page":"37S","article-title":"Real-world experience in the treatment of severe atopic dermatitis with dupilumab in Zurich, Switzerland","volume":"148","author":"Bersuch","year":"2018","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.051_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry","volume":"75","author":"Ariens","year":"2020","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.051_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjd.18179","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data","volume":"182","author":"de Wijs","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.051_bib25","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaad.2020.08.051_bib26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jaad.2018.12.048","article-title":"A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis","volume":"80","author":"Chipalkatti","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5 suppl","key":"10.1016\/j.jaad.2020.08.051_bib27","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.jid.2019.03.768","article-title":"692 Real-world effectiveness of dupilumab based on Investigator Global Assessment (IGA) and peak Pruritus Numerical Rating Scale (PNRS) scores","volume":"139","author":"Eichenfield","year":"2019","journal-title":"J Investig Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.051_bib28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2019.10.010","article-title":"Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review","volume":"82","author":"Igelman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.051_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaad.2019.09.028","article-title":"The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review","volume":"82","author":"Raffi","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.051_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records","volume":"59","author":"Wang","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.08.051_bib31","article-title":"Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: a multi-institution retrospective chart review","volume":"17","author":"Waldman","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5 suppl","key":"10.1016\/j.jaad.2020.08.051_bib32","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.jid.2019.03.749","article-title":"673 Real-world persistence with dupilumab among adults with atopic dermatitis (AD)","volume":"139","author":"Silverberg","year":"2019","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jaad.2020.08.051_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2018.01.016","article-title":"Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"90","author":"Wang","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2020.08.051_bib34","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with\u00a0dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2020.08.051_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaad.2020.08.051_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2020.08.051_bib37","doi-asserted-by":"crossref","first-page":"e12835","DOI":"10.1111\/sji.12835","article-title":"Antagonism of the interleukin 4 receptor alpha promotes TH 1-signalling among T cells from patients with atopic dermatitis after stimulation","volume":"91","author":"Brogger","year":"2020","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jaad.2020.08.051_bib38","first-page":"278","article-title":"Demodex musculi infestation in genetically immunomodulated mice","volume":"66","author":"Smith","year":"2016","journal-title":"Comp Med"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.051_bib39","doi-asserted-by":"crossref","first-page":"e13023","DOI":"10.1111\/dth.13023","article-title":"Dupilumab and alopecia: a Janus effect","volume":"32","author":"Patruno","year":"2019","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.jaad.2020.08.051_bib40","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","article-title":"Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab","volume":"155","author":"Soria","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.08.051_bib41","article-title":"Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series","author":"de Wijs","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.08.051_bib42","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/jdv.15608","article-title":"Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - International Eczema Council survey and opinion","volume":"33","author":"Thyssen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.08.051_bib43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R D"},{"key":"10.1016\/j.jaad.2020.08.051_bib44","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/bjd.16330","article-title":"Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?","volume":"178","author":"Thyssen","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.08.051_bib45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0161-6420(02)01767-0","article-title":"Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis","volume":"110","author":"Leonardi","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2020.08.051_bib46","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Mennini","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.051_bib47","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/bjd.18452","article-title":"Treatment of Atopic Eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in\u00a0patients with atopic eczema","volume":"182","author":"Bosma","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220324427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220324427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:57:49Z","timestamp":1759273069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220324427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0190962220324427"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.051","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}